| Literature DB >> 25883403 |
Beverley M Essue1, Merel Kimman1, Nina Svenstrup1, Katharina Lindevig Kjoege1, Tracey Lea Laba1, Maree L Hackett1, Stephen Jan1.
Abstract
OBJECTIVE: To determine the nature, scope and effectiveness of interventions to reduce the household economic burden of illness or injury.Entities:
Mesh:
Year: 2014 PMID: 25883403 PMCID: PMC4339963 DOI: 10.2471/BLT.14.139287
Source DB: PubMed Journal: Bull World Health Organ ISSN: 0042-9686 Impact factor: 9.408
Fig. 1Flowchart for the selection of studies on interventions to reduce the household economic burden of ill health
Characteristics of the included studies on interventions to reduce the household economic burden of ill health
| Study | Country | Study design (sample size) | Study objective | Study population | Intervention vs control | Outcomes measured |
|---|---|---|---|---|---|---|
| Jing et al. (2013) | China | CBA ( | To evaluate the impact of the New Cooperative Medical Schemes’ reimbursement policies for chronic disease | Rural households in which one or more members have self-reported chronic disease | Higher reimbursement for essential drugs – e.g. 80% for diabetes and hypertension medications – and outpatient care – e.g. 25% or 40% – for specified chronic diseases vs usual care | Catastrophic health expenditure |
| Heikkinen et al. (2011) | Finland | NRCT ( | To evaluate cost of care between two different modes of delivering patient education | Ambulatory orthopaedic surgery patients | Website containing biophysiological, social and financial information plus email contact with nurse vs face-to-face education | Out-of-pocket costs |
| Barry et al. (2013) | USA | CBA ( | To evaluate the impact of FEHBP parity policy on out-of-pocket costs | Individuals aged ≤ 21 years with MH/SUD | Parity of benefits for MH/SUD services vs usual care | Share of total costs spent on MH/SUD services and mean out-of-pocket costs for MH/SUD |
| Busch et al. (2013) | USA | CBA ( | To evaluate the impact of FEHBP parity policy on spending and intensity of service use | Enrolees of FEHBP with bipolar disorder, major depression or adjustment disorder | Parity of benefits for MH/SUD services vs usual care | Out-of-pocket costs and health-service utilization |
| Choudhry et al. (2011) | USA | RCT ( | To evaluate the effect of providing full prescription drug coverage | Individuals with a principal or secondary diagnosis of acute myocardial infarction | Full prescription drug coverage vs usual coverage | Medication adherence and health-care spending, including out-of-pocket costs |
| Choudhry et al. (2012) | USA | ITS ( | To evaluate the impact of reductions in drug co-payments | Individuals with diabetes or vascular disease | Co-payment elimination for patients with diabetes and reduction for patients on clopidogrel vs usual coverage | Out-of pocket costs, medication use and health-service utilization |
| Davidoff et al. (2005) | USA | ITS ( | To evaluate the effects of the expansion of the SCHIP | Children with chronic health conditions | Expansion of eligibility for SCHIP vs usual care | Out-of-pocket spending and health-service use |
| Goldman et al. (2006) | USA | ITS ( | To evaluate the impact of parity in insurance benefits | Enrolees of the FEHBP accessing MH/SUD services | Parity of benefits for MH/SUD services vs usual care | Rate of MH/SUD utilization, out-of-pocket costs and total spending |
| Van Houtven et al. (2013) | USA | RCT ( | To evaluate the effect of a multicomponent intervention for caregivers of older adults | Caregivers of patients with Alzheimer or Parkinson diseases | Multicomponent training over 24 weeks for caregivers via the ASSIST programme vs social phone contacts while on waiting list | Out-of-pocket costs |
ASSIST: Assistance, Support, and Self-health Initiated through Skill Training; CBA: controlled before-and-after study; FEHBP: Federal Employees Health Benefits Program; ITS: interrupted time series; MH/SUD: mental health and substance use disorders; NRCT: nonrandomized controlled trial; RCT: randomized controlled trial; SCHIP: State Children’s Health Insurance Program: USA: United States of America.
Characteristics of interventions investigated in the included studies on interventions to reduce the household economic burden of ill health
| Study | Intervention details | Setting | Target population |
|---|---|---|---|
| Choudhry et al. (2011) | Health-insurance policy – elimination of co-payments for disease-specific drugs | Health-insurance programme | Enrolees |
| Choudhry et al. (2012) | Health-insurance policy – reduction or elimination of co-payments for disease-specific drugs | Health-insurance programme | Enrolees |
| Jing et al. (2013) | Health-insurance policy – higher reimbursement for outpatient ambulatory services and drugs | County population | Enrolees, rural |
| Davidoff et al. (2005) | Health-insurance policy – extended insurance coverage | Health-insurance programme | Enrolees, children |
| Goldman et al. (2006) | Health-insurance policy – parity of coverage for disease-specific services | Health-insurance programme | Enrolees |
| Barry et al. (2013) | Health-insurance policy – parity of coverage for disease-specific services | Health-insurance programme | Enrolees, children |
| Busch et al. (2013) | Health-insurance policy – parity of coverage for MH/SUD services | Health-insurance programme | Enrolees |
| Heikkinen et al. (2013) | Delivery of information and support using a web-based platform | Health service | Clinic-based population |
| Van Houtven et al. (2013) | Delivery of information and support using telephone and in-person training | Health service | Clinic-based population, caregivers |
MH/SUD: mental health and substance use disorders.
Fig. 2Risk of bias in the randomized and nonrandomized controlled trials and the controlled before-and-after studies on interventions to reduce the household economic burden of ill health
Fig. 3Risk of bias in the interrupted time series studies on interventions to reduce the household economic burden of ill health
Effects of interventions on measures of household economic burden
| Type of measure and study | Source of data | Measure | Relative difference (95% CI) | Reference period (months) | Out-of-pocket cost for control group, mean (SD) | Standardized mean difference (95% CI)a | |
|---|---|---|---|---|---|---|---|
| Choudhry et al. (2011) | Insurance claims | Relative ratio of costs per patient | Prescription drugs: 0.70 (0.65 to 0.75) | < 0.001 | 12 | 1164 (1331) | −0.30 (−0.35 to −0.25) |
| Non-drug: 0.82 (0.72 to 0.94) | 0.005 | 12 | 618 (1480) | −0.11 (−0.17 to −0.06) | |||
| All: 0.74 (0.68 to 0.80) | < 0.001 | 12 | 1781 (2263) | −0.26 (−0.31 to −0.20) | |||
| Cardiovascular-specific, prescription drugs: 0.49 (0.46 to 0.53) | < 0.001 | 12 | 665 (721) | −0.58 (−0.64 to −0.53) | |||
| Cardiovascular-specific, non-drug: 0.91 (0.82 to 1.00) | 0.05 | 12 | 235 (349) | −0.10 (−0.15 to −0.04) | |||
| Cardiovascular-specific, total: 0.60 (0.56 to 0.64) | 0.001 | 12 | 900 (888) | −0.50 (−0.55 to −0.45) | |||
| Choudhry et al. (2012) | Insurance claims | Relative ratio of costs per patient | Statin, medication and insurance co-payments: 0.05 (NR)b | NR | 1 | 11.95 (11.44) | −1.02 (−1.06 to −0.90) |
| Statin, medical: 0.90 (0.83 to 0.98)b | NR | 1 | NR | – | |||
| Statin, pharmacy: 0.65 (0.62 to 0.68)b | NR | 1 | NR | – | |||
| Statin, total: 0.79 (0.75 to 0.83)b | NR | 1 | NR | – | |||
| Clopidogrel, medication and insurance co-payments: 0.61 (NR)b | NR | 1 | 14.43 (13.38) | −0.43 (−0.50 to −0.35) | |||
| Clopidogrel, medical: 0.76 (0.61 to 0.94)b | NR | 1 | NR | – | |||
| Clopidogrel, pharmacy: 0.72 (0.67 to 0.76)b | NR | 1 | NR | – | |||
| Clopidogrel, total: 0.74 (0.66 to 0.82)b | NR | 1 | NR | – | |||
| Davidoff et al. (2005) | Self-report | Change in percentage of patients paying | At least US$ 2000: −1.3 (−8.94 to 6.34) | 0.05 | 12 | NR | – |
| US$ 500–1999: −4.0 (−14.39 to 6.39) | > 0.05 | 12 | NR | – | |||
| US$ 1–499: 3.2 (−7.19 to 13.59) | > 0.05 | 12 | NR | – | |||
| Nothing: 2.2 (−2.31 to 6.71) | > 0.05 | 12 | NR | – | |||
| Goldman et al. (2006) | Insurance claims | Difference in difference change in mean costs per patient of MH/SUD services, US$ | National PPO: 4.48 (0.91 to 8.06) | ≤ 0.05 | 24 | NR | – |
| Mid-Atlantic PPO 1: −15.43 (−26.14 to −4.73) | ≤ 0.05 | 24 | NR | – | |||
| Mid-Atlantic PPO 2: −13.82 (−23.96 to −3.67) | ≤ 0.05 | 24 | NR | – | |||
| Northeastern PPO 1: −8.78 (−21.14 to 3.57) | > 0.05 | 24 | NR | – | |||
| Northeastern PPO 2: −48·12 (−66.85 to −29.39) | ≤ 0.05 | 24 | NR | – | |||
| Western PPO: −49.80 (−61.17 to −38.43) | ≤ 0.05 | 24 | NR | – | |||
| Southern PPO: −87.06 (−99.73 to −74.38) | ≤ 0.05 | 24 | NR | – | |||
| Barry et al. (2013) | Insurance claims | Difference in difference change in mean costs per patient of MH/SUD services, US$ | −178 (−257 to −97)c | ≤ 0.05 | 12 | NR | – |
| Busch et al. (2013) | Insurance claims | Difference in difference change in mean costs per patient, US$ | Bipolar disorder: −148 (−217 to −85) | NR | 12 | NR | – |
| Major depression: −100 (−123 to −77) | NR | 12 | NR | – | |||
| Adjustment disorder: −68 (−84 to −54) | NR | 12 | NR | – | |||
| Heikkinen et al. (2011) | Self-report | Relative ratio of costs per patient | Total: 0.98 (NR) | NR | NR | 240 (264) | −0.02 (−0.35 to 0.32) |
| Hospital: 1.04 (NR) | NR | NR | 124 (134) | 0.04 (−0.30 to 0.37) | |||
| Laboratory tests and X-ray examinations: 0.45 (NR) | NR | NR | 216 (242) | −0.64 (−1.29 to 0.01) | |||
| Medication: 1.16 (NR) | NR | NR | 26.2 (19.29) | 0.17 (−0.20 to 0.53) | |||
| Physician fees: 0.95 (NR) | NR | NR | 51.39 (64.24) | −0.05 (−0.58 to 0.48) | |||
| Travel: 1.17 (NR) | NR | NR | 18.73 (24.79) | 0.11 (−0.36 to 0.57) | |||
| Equipment: 1.10 (NR) | NR | NR | 11.63 (8.03) | 0.14 (−0.41 to 0.69) | |||
| Medical certificate: 0.83 (NR) | NR | NR | 8.02 (9.09) | −0.15 (−0.64 to 0.34) | |||
| Escort: 4.44 (NR) | NR | NR | 7.88 (9.19) | 0.94 (−0.45 to 2.32) | |||
| Utility bills: 1.71 (NR) | NR | NR | 2.49 (1.70) | 0.82 (−0.10 to 1.73) | |||
| Parking: 1.27 (NR) | NR | NR | 1.49 (1.85) | 0.23 (−0.39 to 0.86) | |||
| Additional: 0.29 (NR) | NR | NR | 120 (144) | −0.68 (−2.42 to 1.06) | |||
| Van Houtven et al. (2013) | Self-report | Logged costs per patient, US$ | Caregiver: −54.32 (−143.81 to 35.17)d | NR | 1 | NR | – |
| Care-recipient: 192.25 (−361.86 to 746.36)d | NR | 1 | NR | – | |||
| Total: 57.42 (−461.39 to 576.23)d | NR | 1 | NR | – | |||
| Jing et al. (2013) | Self-report | Difference in difference change in proportion of households, % | 0.53 (NR) | > 0.05 | 12 | −2.10 (5.75) | NR |
| Davidoff et al. (2005) | Self-report | Change in percentage of patients who delayed seeking care due to cost | −1.7 (−6.6 to 3.2) | NR | 12 | NR | – |
| Van Houtven et al. (2013) | Self-report | Probability that household paid | Any caregiver costs: 0.26 (0.09 to 0.44) | NR | 1 | NR | – |
| Any care-recipient costs: 0.11 (−0.06 to 0.29) | NR | 1 | NR | – | |||
| Any costs: 0.23 (0.12 to 0.34) | NR | 1 | NR | – |
CI: confidence interval; MH/SUD: mental health and substance use disorders; NR: not reported; PPO: preferred provider organization; SD: standard deviation; US$: United States dollars.
a The difference in mean effects in the intervention and control groups, divided by the pooled standard deviation.
b Relative changes in out-of-pocket costs were adjusted for age, sex, income, race, coronary artery disease, congestive heart failure, diabetes, hypertension, Charlson comorbidity score, number of hospitalizations and prescription drugs on enrolment.
c Difference in difference analysis of gender-, age- and area-adjusted change in annual out-of-pocket costs among those in at least the 90th percentile of MH/SUD treatment expenditure. The corresponding proportion of total MH/SUD costs fell significantly by 5% (P ≤ 0.05).
d Confidence interval calculated from reported standard error.
Other patient outcomes assessed in the included studies
| Patient outcome | Choudhry et al. (2011) | Choudhry et al. (2012) | Davidoff et al. (2005) | Goldman et al. (2006) | Jing et al. (2013) | Barry et al. (2013) | Busch et al. (2013) | Heikkinen et al. (2011) | Van Houtven et al. (2013) |
|---|---|---|---|---|---|---|---|---|---|
| Readmission for major vascular event or coronary revascularization | Yes | No | No | No | No | No | No | No | No |
| Rate of total major vascular events or revascularization | Yes | Yes | No | No | No | No | No | No | No |
| Private health-insurance coverage | No | No | Yes | No | No | No | No | No | No |
| Emergency presentations | No | Yes | No | Yes | No | No | No | No | No |
| Hospital admissions | No | Yes | No | Yes | No | No | Yes | Yes | No |
| Physician visits | No | Yes | No | Yes | No | No | Yes | Yes | No |
| Othera | No | No | No | No | No | No | No | Yes | No |
| Unmet needsb | No | No | No | Yes | No | No | No | No | No |
| Medication possession ratioc | Yes | No | No | No | No | No | No | No | No |
| Full adherence | Yes | No | No | No | No | No | No | No | No |
| Medication filling | No | Yes | No | No | No | No | No | No | No |
| Costs to private health insurer | Yes | Yes | No | No | No | No | No | No | No |
| Time costsd | No | No | No | No | No | No | No | Yes | No |
a First aid, nurses and other health-care professionals.
b Medical, dental, prescription drugs and mental health services.
c The number of days a patient had a supply of each medication class available divided by the number of days the patient was eligible for that medication.
d Including work and free time spent attending laboratory tests, X-ray examinations and receiving patient-targeted education and time spent off work, on sick leave.